Actively Recruiting
Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Led by Associação Centro de Apoio Tecnológico Agro Alimentar · Updated on 2025-01-06
33
Participants Needed
2
Research Sites
20 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Kombucha, a fermented beverage made from Camellia sinensis tea (black, oolong, or green) with sugar and a symbiotic culture of bacteria and yeast (SCOBY), has gained global attention for its potential health benefits. Factors like the type and amount of sugar substrate, fermentation time, and temperature significantly influence its organic compounds, total phenolics, vitamin content, and alcohol levels. In a previous study, kombucha's impact on glucose tolerance, insulin sensitivity, body composition, and liver function was tested in male prediabetic mice with diet-induced obesity. Daily supplementation (200 µL per mouse) improved glucose tolerance after nine days (equivalent to one year in humans) and reduced liver steatosis, despite no changes in body composition. Although kombucha has been associated with antioxidant, antimicrobial, probiotic, antidiabetic, and anticancer activities, strong scientific evidence in humans remains limited. Further clinical studies are needed to substantiate kombucha's health benefits in humans.
CONDITIONS
Official Title
Kombucha in Overweight and Obese: Live Vs. Pasteurized Effects on Microbiota, Metabolism, and Liver Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged between 18 and 60 years
- Body Mass Index (BMI) between 25 kg/m² and 34.9 kg/m²
- Both biological sexes eligible
- Willingness to comply with the study protocol and sign informed consent
You will not qualify if you...
- Sensitivity to kombucha
- Consumption of kombucha or other fermented products within 3 weeks before or during the study
- Antibiotic use within 6 months before the study
- Use of probiotics, prebiotics, fibers, or laxatives within 6 weeks before recruitment
- Following specific dietary regimens or treatments (e.g., vegan, high protein)
- Excessive alcohol consumption or smoking
- Diagnosis of gastrointestinal, hormonal, thyroid, autoimmune, psychiatric diseases, or diabetes types 1 or 2
- Use of proton pump inhibitors, antidiabetic drugs, insulin, or statins
- Presence of insulin sensitivity
- Pregnant or lactating women
- Tooth sensitivity
- Participation in another clinical trial within the last 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Centro de Apoio Tecnológico Agro Alimentar (CATAA)
Castelo Branco, Castelo Branco District, Portugal, 6000-459
Actively Recruiting
2
Centro de Apoio Tecnológico Agro Alimentar (CATAA) (facilities temporarily provided by the Affidea clinical analysis center)
Covilha, Portugal, 6200-077
Actively Recruiting
Research Team
I
Inês Brandão, PhD
CONTACT
F
Filomena Pereira, Nutritionist
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here